Mostrando 10 resultados de: 16
Filtros aplicados
Publisher
Journal of Alzheimer's Disease(2)
Biochimica et Biophysica Acta - Molecular Basis of Disease(1)
Biomedicine and Pharmacotherapy(1)
Current Pharmaceutical Design(1)
Experimental Gerontology(1)
Área temáticas
Enfermedades(16)
Farmacología y terapéutica(7)
Fisiología humana(6)
Medicina y salud(4)
Ginecología, obstetricia, pediatría, geriatría(2)
Origen
scopus(16)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusAn overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders
ReviewAbstract: Importance of the field: The increase in life expectancy in developed countries has given rise to sePalabras claves:Alzheimer's disease, apoptosis, Neuroprotective drugs, Parkinson's DiseaseAutores:Antoni Camins, Folch J., Junyent F., Pallás M., Sureda F.X., Verdaguer E., Zárate C.B.Fuentes:scopusAntiapoptotic drugs: A therapautic strategy for the prevention of neurodegenerative diseases
ReviewAbstract: The purpose of this review is to discuss potential pathways involved in the pathogenesis of neurodegPalabras claves:Alzheimer's disease, apoptosis, Cyclin-dependent kinases, Glutamate receptors, Neuronal cell death, Neuroprotective drugs. apoptosis, Parkinson's DiseaseAutores:Antoni Camins, Auladell C., Canudas A.M., Folch J., Junyent F., Pallás M., Pelegrí Gabalda C., Sureda F.X., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusA metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusDexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
ArticleAbstract: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a rePalabras claves:Alzheimer's disease, APPswe/PS1dE9, Dexibuprofen, hippocampus, insulin receptor, Memory impairment, Mitochondria, TauAutores:Antoni Camins, Auladell C., Busquets O., Ettcheto M., Folch J., García M.L., Olloquequi J., Pallás M., Pons L., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusEvaluation of neuropathological effects of a high-fat diet in a presymptomatic Alzheimer's disease stage in APP/PS1 mice
ArticleAbstract: Alzheimer's disease (AD) is currently an incurable aging-related neurodegenerative disorder. RecentPalabras claves:Alzheimer's disease, APPswe/PS1dE9, hippocampus, insulin receptor, Mitochondria, TauAutores:Alva N., Antoni Camins, Auladell C., Carbonell T., Ettcheto M., Folch J., Pallás M., Pedros I., Petrov D., Zárate C.B.Fuentes:scopusEarly alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease
ArticleAbstract: The present study had focused on the behavioral phenotype and gene expression profile of molecules rPalabras claves:Alzheimer's disease, APPswe/PS1dE9, hippocampus, insulin receptor, Mitochondria, TauAutores:Allgaier M., Antoni Camins, Auladell C., Barroso E., Casadesús G., Folch J., Pallás M., Pedros I., Petrov D., Sureda F.X., Vázquez-Carrera M., Zárate C.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusNew potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9
ArticleAbstract: Dexibuprofen loaded pegylated poly(lactic-co-glycolic) nanospheres prepared by solvent diffusion metPalabras claves:Alzheimer's disease, Blood–Brain barrier, Dexibuprofen, Nanoparticles, Nanospheres, PLGA-PEGAutores:Antoni Camins, Calpena A.C., Egea M.A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusHypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice
ArticleAbstract: Previous studies suggest that Alzheimer's disease (AD) neurobiology could not be explained solely byPalabras claves:Alzheimer's disease, APP/PS1, cholesterol, hippocampus, LDLR-/-, OXPHOSAutores:Alegret M., Antoni Camins, De Lemos M.L., Ettcheto M., Folch J., Laguna J.C., Pallás M., Pedros I., Petrov D.Fuentes:scopus